Table 2.
Females | Males | |||
---|---|---|---|---|
Control group | LPS 1 | Control group | LPS 1 | |
IL-2 (pg/ml) | 4403 (2378–6093) | 456.3* (386.1–617.8) | 141.7# (124.6–158.8) | 474.4* (426.1–826.2) |
IL-4 (pg/ml) | 0.2 (0–0.9) | 0.4 (0.1–0.8) | 0.1 (0–0.3) | 0.3 (0–0.6) |
IFN-γ (pg/ml) | 48.9 (32.2–57.9) | 0* (0-0) | 0.9# (0.3–10.9) | 0* (0-0) |
TNF-α (pg/ml) | 169.7 (123.6–255.8) | 89.8* (67.4–128.8) | 10.8# (1.3–13.5) | 51.2* (41.8–70.1) |
Neopterin (нмольл) | 7 (5.7–10.8) | 14.2* (11.6–14.2) | 9.1 (7.1–10.4) | 7.3 (6–8.7) |
TGF-β (ng/ml) | 18.6 (16.1–20.9) | 14.5 (15.2–18.2) | 18.9 (16.8–27.1) | 17 (15.2–18.2) |
Med: median, 25%–75%: interquartile range, LPS 1: the 1st day after LPS injection, *differences which are statistically significant as compared with the corresponding control group, and #differences which are statistically significant between control groups of males and females.